Histamine Releasing Factor/Translationally Controlled Tumor Protein: History, Functions and Clinical Implications
Susan M. MacDonald*
Identifiers and Pagination:Year: 2012
First Page: 12
Last Page: 18
Publisher Id: TOALLJ-5-12
Article History:Received Date: 25/1/2012
Revision Received Date: 10/2/2012
Acceptance Date: 17/2/2012
Electronic publication date: 18/5/2012
Collection year: 2012
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Histamine Releasing Factor (HRF) also known as Translationally Controlled Tumor Protein (TCTP) is a ubiquitous, novel protein that has both intracellular and extracellular functions. The purpose of this review is to highlight the background history of the molecule, the clinical implications and focus on the extracellular functions. Specifically the cells and the cytokines that are produced when stimulated by HRF/TCTP will be delineated as well as the signal transduction pathway that HRF/TCTP elicits will be described. Originally it was thought that HRF/TCTP interacted with IgE. Subsequently, cells that do not bind IgE also respond to HRF/TCTP and the interaction with IgE was questioned. Now, very recently, HRF/TCTP or at least its mouse counterpart appears to interact with some, but not all IgE and IgG molecules. HRF/TCTP has been shown to activate multiple human cells including basophils, eosinophils, T cells and B cells. Many of the cells that are activated by HRF/TCTP participate in the allergic response, leading to the conclusion that the extracellular functions of HRF/TCTP could exacerbate the allergic, inflammatory response.